Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Extrastriatal dopamine D(2) receptor binding in Huntington's disease.
Esmaeilzadeh M, Farde L, Karlsson P, Varrone A, Halldin C, Waters S, Tedroff J. Esmaeilzadeh M, et al. Among authors: tedroff j. Hum Brain Mapp. 2011 Oct;32(10):1626-36. doi: 10.1002/hbm.21134. Epub 2010 Sep 30. Hum Brain Mapp. 2011. PMID: 20886576 Free PMC article.
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators. de Yebenes JG, et al. Among authors: tedroff j. Lancet Neurol. 2011 Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2. Epub 2011 Nov 7. Lancet Neurol. 2011. PMID: 22071279 Clinical Trial.
Reversible chorea in primary antiphospholipid syndrome.
Sundén-Cullberg J, Tedroff J, Aquilonius SM. Sundén-Cullberg J, et al. Among authors: tedroff j. Mov Disord. 1998 Jan;13(1):147-9. doi: 10.1002/mds.870130127. Mov Disord. 1998. PMID: 9452340 Review.
Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography.
Neu H, Hartvig P, Torstenson R, Fasth KJ, Sonesson C, Waters N, Carlsson A, Tedroff J, Långström B. Neu H, et al. Among authors: tedroff j. Nucl Med Biol. 1997 Aug;24(6):507-11. doi: 10.1016/s0969-8051(97)00023-1. Nucl Med Biol. 1997. PMID: 9316077
Kinetic analysis using positron emission tomography.
Hartvig P, Tedroff J, Lilja A, Lindner KJ, Långström B. Hartvig P, et al. Among authors: tedroff j. Arch Toxicol Suppl. 1994;16:223-32. doi: 10.1007/978-3-642-78640-2_25. Arch Toxicol Suppl. 1994. PMID: 8192585 Review. No abstract available.
Tetrahydrobiopterin and dopamine release.
Watanabe Y, Mataga N, Imamura K, Onoe H, Koshimura K, Miwa S, Hartvig P, Tedroff J, Bjurling P, Långström B. Watanabe Y, et al. Among authors: tedroff j. Jpn J Psychiatry Neurol. 1991 Jun;45(2):513-4. doi: 10.1111/j.1440-1819.1991.tb02537.x. Jpn J Psychiatry Neurol. 1991. PMID: 1684829 No abstract available.
(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.
Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, Edling M, Svanberg B, Ljung E, Gunnergren J, McLean SL, Grayson B, Idris NF, Neill JC, Sonesson C. Hjorth S, et al. Among authors: tedroff j. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. doi: 10.1124/jpet.120.000037. Epub 2020 Jun 30. J Pharmacol Exp Ther. 2020. PMID: 32605972
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.
Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N. Waters S, et al. Among authors: tedroff j. J Pharmacol Exp Ther. 2020 Jul;374(1):113-125. doi: 10.1124/jpet.119.264226. Epub 2020 May 1. J Pharmacol Exp Ther. 2020. PMID: 32358046
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators. Svenningsson P, et al. Among authors: tedroff j. Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. Epub 2020 Mar 21. Mov Disord. 2020. PMID: 32198802 Clinical Trial.
Discrepancies in reporting the CAG repeat lengths for Huntington's disease.
Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network. Quarrell OW, et al. Eur J Hum Genet. 2012 Jan;20(1):20-6. doi: 10.1038/ejhg.2011.136. Epub 2011 Aug 3. Eur J Hum Genet. 2012. PMID: 21811303 Free PMC article.
Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.
Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Orth M, et al. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12. doi: 10.1136/jnnp.2010.209668. Epub 2010 Nov 19. J Neurol Neurosurg Psychiatry. 2011. PMID: 21097549 No abstract available.